Taxotere®, Eloxatin® and Xeloda® (TEX) in Combination With Herceptin® as Treatment for HER2 Positive Non-resectable Cancer

NCT01295086 · clinicaltrials.gov ↗

NA

Phase

COMPLETED

Status

27

Enrollment

OTHER

Sponsor class

Conditions

Adenocarcinoma

Interventions

DRUG: Docetaxel
DRUG: Oxaliplatin
DRUG: Capecitabine
DRUG: Trastuzumab

Sponsor

Odense University Hospital

Collaborators

[object Object]
[object Object]
[object Object]